Beyond one pill, once daily: current challenges of antiretroviral therapy management in the United States

References

• Antiretroviral Therapy Cohort C. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. Lancet HIV. 2017 Aug;4(8):e349–e356. PubMed PMID: 28501495; PubMed Central PMCID: PMCPMC5555438.
   PubMed Web of Science ®Google Scholar
• Centers for Disease C. Revision of the case definition of acquired immunodeficiency syndrome for national reporting–United States. MMWR Morb Mortal Wkly Rep. 1985 Jun 28;34(25):373–375. PubMed PMID: 2989677.
   PubMedGoogle Scholar
• Centers for Disease C. Pneumocystis pneumonia–los Angeles. MMWR Morb Mortal Wkly Rep. 1981 Jun 5;30(21):250–252. PubMed PMID: 6265753.
   PubMedGoogle Scholar
• Gandhi M, Gandhi RT. Single-pill combination regimens for treatment of HIV-1 infection. N Engl J Med. 2014 Jul 17;371(3):248–259. PubMed PMID: 25014689.
   PubMed Web of Science ®Google Scholar
• Broder S. The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic. Antiviral Res. 2010 Jan;85(1):1–18. PubMed PMID: 20018391; PubMed Central PMCID: PMCPMC2815149.
   PubMed Web of Science ®Google Scholar
• Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987 Jul 23;317(4):185–191. PubMed PMID: 3299089.
   PubMed Web of Science ®Google Scholar
• Vella S, Schwartlander B, Sow SP, et al. The history of antiretroviral therapy and of its implementation in resource-limited areas of the world. AIDS. 2012 Jun 19;26(10):1231–1241. PubMed PMID: 22706009.
   PubMed Web of Science ®Google Scholar
• Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 study team. N Engl J Med. 1997 Sep 11;337(11):725–733. PubMed PMID: 9287227.
   PubMed Web of Science ®Google Scholar
• Gulick RM, Mellors JW, Havlir D, et al. 3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine. Ann Intern Med. 2000 Jul 4;133(1):35–39. PubMed PMID: 10877738.
   PubMed Web of Science ®Google Scholar
• Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. updated 2019 Jan 7]. Available from: https://aidsinfo.nih.gov/guidelines.
   Google Scholar
• Saag MS, Benson CA, Gandhi RT, et al. Antiretroviral drugs for treatment and prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society-USA Panel. JAMA. 2018 Jul 24;320(4):379–396. PubMed PMID: 30043070; PubMed Central PMCID: PMCPMC6415748.
   PubMed Web of Science ®Google Scholar
• Le T, Wright EJ, Smith DM, et al. Enhanced CD4+ T-cell recovery with earlier HIV-1 antiretroviral therapy. N Engl J Med. 2013 Jan 17;368(3):218–230. PubMed PMID: 23323898; PubMed Central PMCID: PMCPMC3657555.
   PubMed Web of Science ®Google Scholar
• Oxenius A, Price DA, Easterbrook PJ, et al. Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes. Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3382–3387. PubMed PMID: 10737796; PubMed Central PMCID: PMCPMC16248.
   PubMed Web of Science ®Google Scholar
• Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994 Nov 3;331(18):1173–1180. PubMed PMID: 7935654.
   PubMed Web of Science ®Google Scholar
• Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011 Aug 11;365(6):493–505. PubMed PMID: 21767103; PubMed Central PMCID: PMCPMC3200068.
   PubMed Web of Science ®Google Scholar
• Rodger AJ, Cambiano V, Bruun T, et al. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. Lancet. 2019 Jun 15;393(10189):2428–2438. PubMed PMID: 31056293; PubMed Central PMCID: PMCPMC6584382.
   PubMed Web of Science ®Google Scholar
• Palella FJ Jr., Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. N Engl J Med. 1998 Mar 26;338(13):853–860. PubMed PMID: 9516219.
   PubMed Web of Science ®Google Scholar
• Lundgren JD, Babiker AG, Gordin F, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015 Aug 27;373(9):795–807. PubMed PMID: 26192873; PubMed Central PMCID: PMCPMC4569751.
   PubMed Web of Science ®Google Scholar
• Group TAS, Danel C, Moh R, et al. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med. 2015 Aug 27;373(9):808–822. PubMed PMID: 26193126.
   PubMed Web of Science ®Google Scholar
• Rosen S, Maskew M, Fox MP, et al. Initiating antiretroviral therapy for HIV at a patient’s first clinic visit: the RapIT randomized controlled trial. PLoS Med. 2016 May;13(5):e1002015. PubMed PMID: 27163694; PubMed Central PMCID: PMCPMC4862681.
   PubMed Web of Science ®Google Scholar
• Koenig SP, Dorvil N, Devieux JG, et al. Same-day HIV testing with initiation of antiretroviral therapy versus standard care for persons living with HIV: A randomized unblinded trial. PLoS Med. 2017 Jul;14(7):e1002357. PubMed PMID: 28742880; PubMed Central PMCID: PMCPMC5526526.
   PubMed Web of Science ®Google Scholar
• Labhardt ND, Ringera I, Lejone TI, et al. Effect of offering same-day ART vs usual health facility referral during home-based HIV testing on linkage to care and viral suppression among adults with HIV in lesotho: the CASCADE randomized clinical trial. JAMA. 2018 Mar 20;319(11):1103–1112. PubMed PMID: 29509839; PubMed Central PMCID: PMCPMC5885884.
   PubMed Web of Science ®Google Scholar
• Amanyire G, Semitala FC, Namusobya J, et al. Effects of a multicomponent intervention to streamline initiation of antiretroviral therapy in Africa: a stepped-wedge cluster-randomised trial. Lancet HIV. 2016 Nov;3(11):e539–e548. PubMed PMID: 27658873; PubMed Central PMCID: PMCPMC5408866.
   PubMed Web of Science ®Google Scholar
• Pilcher CD, Ospina-Norvell C, Dasgupta A, et al. The effect of same-day observed initiation of antiretroviral therapy on HIV viral load and treatment outcomes in a US public health setting. J Acquir Immune Defic Syndr. 2017 Jan 1;74(1):44–51. PubMed PMID: 27434707; PubMed Central PMCID: PMCPMC5140684.
   PubMed Web of Science ®Google Scholar
• Colasanti J, Sumitani J, Mehta CC, et al. Implementation of a rapid entry program decreases time to viral suppression among vulnerable persons living with HIV in the Southern United States. Open Forum Infect Dis. 2018 Jun;5(6):ofy104. PubMed PMID: 29992172; PubMed Central PMCID: PMCPMC6022569.
   PubMed Web of Science ®Google Scholar
• Coffey S, Bacchetti P, Sachdev D, et al. RAPID ART: high virologic suppression rates with immediate ART initiation in a vulnerable urban clinic population. AIDS. 2018 Dec 21. DOI:10.1097/QAD.0000000000002124. PubMed PMID: 30585846.
   Web of Science ®Google Scholar
• Ford N, Migone C, Calmy A, et al. Benefits and risks of rapid initiation of antiretroviral therapy. AIDS. 2018 Jan 2;32(1):17–23. PubMed PMID: 29112073; PubMed Central PMCID: PMCPMC5732637.
   PubMed Web of Science ®Google Scholar
• Strain MC, Little SJ, Daar ES, et al. Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. J Infect Dis. 2005 May 1;191(9):1410–1418. PubMed PMID: 15809898.
   PubMed Web of Science ®Google Scholar
• Chun TW, Justement JS, Moir S, et al. Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus. J Infect Dis. 2007 Jun 15;195(12):1762–1764. PubMed PMID: 17492591.
   PubMed Web of Science ®Google Scholar
• Jain V, Hartogensis W, Bacchetti P, et al. Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size. J Infect Dis. 2013 Oct 15;208(8):1202–1211. PubMed PMID: 23852127; PubMed Central PMCID: PMCPMC3778965.
   PubMed Web of Science ®Google Scholar
• Hey-Cunningham WJ, Murray JM, Natarajan V, et al. Early antiretroviral therapy with raltegravir generates sustained reductions in HIV reservoirs but not lower T-cell activation levels. AIDS. 2015 May 15;29(8):911–919. PubMed PMID: 25730509.
   PubMed Web of Science ®Google Scholar
• Martinez-Bonet M, Puertas MC, Fortuny C, et al. Establishment and replenishment of the viral reservoir in perinatally HIV-1-infected children initiating very early antiretroviral therapy. Clin Infect Dis. 2015 Oct 1;61(7):1169–1178. PubMed PMID: 26063721; PubMed Central PMCID: PMCPMC4560905.
   PubMed Web of Science ®Google Scholar
• Novelli S, Lecuroux C, Avettand-Fenoel V, et al. Long-term therapeutic impact of the timing of antiretroviral therapy in patients diagnosed with primary human immunodeficiency virus type 1 infection. Clin Infect Dis. 2018 May 2;66(10):1519–1527. PubMed PMID: 29211834.
   PubMed Web of Science ®Google Scholar
• Aberg JA, Gallant JE, Ghanem KG, et al. Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV medicine association of the infectious diseases society of America. Clin Infect Dis. 2014 Jan;58(1):1–10. PubMed PMID: 24343580.
   PubMed Web of Science ®Google Scholar
• Abdool Karim SS, Naidoo K, Grobler A, et al. Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med. 2011 Oct 20;365(16):1492–1501. PubMed PMID: 22010915; PubMed Central PMCID: PMCPMC3233684.
   PubMed Web of Science ®Google Scholar
• Blanc FX, Sok T, Laureillard D, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med. 2011 Oct 20;365(16):1471–1481. PubMed PMID: 22010913; PubMed Central PMCID: PMCPMC4879711.
   PubMed Web of Science ®Google Scholar
• Abdool Karim SS, Naidoo K, Grobler A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med. 2010 Feb 25;362(8):697–706. PubMed PMID: 20181971; PubMed Central PMCID: PMCPMC3076221.
   PubMed Web of Science ®Google Scholar
• Torok ME, Yen NT, Chau TT, et al. Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)–associated tuberculous meningitis. Clin Infect Dis. 2011 Jun;52(11):1374–1383. PubMed PMID: 21596680; PubMed Central PMCID: PMCPMC4340579.
   PubMed Web of Science ®Google Scholar
• Boulware DR, Meya DB, Muzoora C, et al. Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis. N Engl J Med. 2014 Jun 26;370(26):2487–2498. PubMed PMID: 24963568; PubMed Central PMCID: PMCPMC4127879.
   PubMed Web of Science ®Google Scholar
• Panichsillapakit T, Smith DM, Wertheim JO, et al. Prevalence of Transmitted HIV Drug Resistance Among Recently Infected Persons in San Diego, CA 1996-2013. J Acquir Immune Defic Syndr. 2016 Feb 1;71(2):228–236. PubMed PMID: 26413846; PubMed Central PMCID: PMCPMC4712087.
   PubMed Web of Science ®Google Scholar
• Rhee SY, Clutter D, Fessel WJ, et al. Trends in the molecular epidemiology and genetic mechanisms of transmitted human immunodeficiency virus type 1 drug resistance in a large US clinic population. Clin Infect Dis. 2019 Jan 7;68(2):213–221. PubMed PMID: 29846534; PubMed Central PMCID: PMCPMC6321854.
   PubMed Web of Science ®Google Scholar
• Amico KR, Mayer KH. HIV preexposure prophylaxis: a review. JAMA. 2018 Mar 27;319(12):1261–1268. PubMed PMID: 29584848.
   PubMed Web of Science ®Google Scholar
• Singh KP, Crane M, Audsley J, et al. HIV-hepatitis B virus coinfection: epidemiology, pathogenesis, and treatment. AIDS. 2017 Sep 24;31(15):2035–2052. PubMed PMID: 28692539; PubMed Central PMCID: PMCPMC5661989.
   PubMed Web of Science ®Google Scholar
• Gemtessa TA, Chirch LM. Update on Hepatitis C Virus and HIV Coinfection. J Clin Transl Hepatol. 2013 Dec;1(2):109–115. PubMed PMID: 26355698; PubMed Central PMCID: PMCPMC4521281.
   PubMedGoogle Scholar
• Menard A, Colson P, Catherine D, et al. First Real Life Evidence of New Direct-acting Antivirals (DAA) in Co-infected HIV HCV Patients: better than Ever. Clin Infect Dis. 2016 Apr 1;62(7):947–949. PubMed PMID: 26740514.
   PubMed Web of Science ®Google Scholar
• Panel A-IHG. Hepatitis C Guidance 2018 Update: AASLD-IDSA recommendations for testing, managing, and treating Hepatitis C virus infection. Clin Infect Dis. 2018 Oct 30;67(10):1477–1492. PubMed PMID: 30215672.
   PubMed Web of Science ®Google Scholar
• Wenning LA, Hanley WD, Brainard DM, et al. Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir. Antimicrob Agents Chemother. 2009 Jul;53(7):2852–2856. PubMed PMID: 19433563; PubMed Central PMCID: PMCPMC2704654.
   PubMed Web of Science ®Google Scholar
• Dooley KE, Sayre P, Borland J, et al. Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects. J Acquir Immune Defic Syndr. 2013 Jan 1;62(1):21–27. PubMed PMID: 23075918.
   PubMed Web of Science ®Google Scholar
• Dooley KE, Kaplan R, Mwelase N, et al. Dolutegravir-based antiretroviral therapy for patients co-infected with tuberculosis and HIV: a multicenter, noncomparative, open-label, randomized trial. Clin Infect Dis. 2019 Mar 28. DOI:10.1093/cid/ciz256. PubMed PMID: 30918967.
   Google Scholar
• Flandre P, Pugliese P, Cuzin L, et al. Risk factors of chronic kidney disease in HIV-infected patients. Clin J Am Soc Nephrol. 2011 Jul;6(7):1700–1707. PubMed PMID: 21566114.
   PubMed Web of Science ®Google Scholar
• Doshi S, Ucanda M, Hart R, et al. Incidence and Risk Factors for Renal Disease in an Outpatient Cohort of HIV-Infected Patients on Antiretroviral Therapy. Kidney Int Rep. 2019 Aug;4(8):1075–1084. PubMed PMID: 31440698; PubMed Central PMCID: PMCPMC6698302.
   PubMed Web of Science ®Google Scholar
• Roling J, Schmid H, Fischereder M, et al. HIV-associated renal diseases and highly active antiretroviral therapy-induced nephropathy. Clin Infect Dis. 2006 May 15;42(10):1488–1495. PubMed PMID: 16619164.
   PubMed Web of Science ®Google Scholar
• Woodward CL, Hall AM, Williams IG, et al. Tenofovir-associated renal and bone toxicity. HIV Med. 2009 Sep;10(8):482–487. PubMed PMID: 19459988.
   PubMed Web of Science ®Google Scholar
• Ray AS, Fordyce MW, Hitchcock MJ. Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus. Antiviral Res. 2016 Jan;125:63–70. PubMed PMID: 26640223.
   PubMed Web of Science ®Google Scholar
• DeJesus E, Haas B, Segal-Maurer S, et al. Superior Efficacy and Improved Renal and Bone Safety After Switching from a Tenofovir Disoproxil Fumarate- to a Tenofovir Alafenamide-Based Regimen Through 96 Weeks of Treatment. AIDS Res Hum Retroviruses. 2018 Apr;34(4):337–342. PubMed PMID: 29368537.
   PubMed Web of Science ®Google Scholar
• Gonciulea A, Wang R, Althoff KN, et al. An increased rate of fracture occurs a decade earlier in HIV+ compared with HIV- men. AIDS. 2017 Jun 19;31(10):1435–1443. PubMed PMID: 28574962; PubMed Central PMCID: PMCPMC5624823.
   PubMed Web of Science ®Google Scholar
• Grant PM, Cotter AG. Tenofovir and bone health. Curr Opin HIV AIDS. 2016 May;11(3):326–332. PubMed PMID: 26859637; PubMed Central PMCID: PMCPMC4844450.
   PubMed Web of Science ®Google Scholar
• Owe-Larsson B, Sall L, Salamon E, et al. HIV infection and psychiatric illness. Afr J Psychiatry (Johannesbg). 2009 May;12(2):115–128. PubMed PMID: 19582313.
   PubMedGoogle Scholar
• Robertson KR, Smurzynski M, Parsons TD, et al. The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS. 2007 Sep 12;21(14):1915–1921. PubMed PMID: 17721099.
   PubMed Web of Science ®Google Scholar
• Arendt G, de Nocker D, von Giesen HJ, et al. Neuropsychiatric side effects of efavirenz therapy. Expert Opin Drug Saf. 2007 Mar;6(2):147–154. PubMed PMID: 17367260.
   PubMed Web of Science ®Google Scholar
• Hoffmann C, Welz T, Sabranski M, et al. Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients. HIV Med. 2017 Jan;18(1):56–63. PubMed PMID: 27860104.
   PubMed Web of Science ®Google Scholar
• Hoffmann C, Llibre JM. Neuropsychiatric Adverse Events with Dolutegravir and Other Integrase Strand Transfer Inhibitors. AIDS Rev. 2019;21(1):4–10. PubMed PMID: 30899113.
   PubMed Web of Science ®Google Scholar
• O'Halloran JA, Cooley SA, Strain JF, et al. Altered neuropsychological performance and reduced brain volumetrics in people living with HIV on integrase strand transfer inhibitors. AIDS. 2019 Jul 15;33(9):1477–1483. PubMed PMID: 31008801.
   PubMed Web of Science ®Google Scholar
• Feinstein MJ, Hsue PY, Benjamin LA, et al. Characteristics, Prevention, and Management of Cardiovascular Disease in People Living With HIV: A Scientific Statement From the American Heart Association. Circulation. 2019 Jul 9;140(2):e98–e124. PubMed PMID: 31154814.
   PubMed Web of Science ®Google Scholar
• Feinstein MJ, Bahiru E, Achenbach C, et al. Patterns of Cardiovascular Mortality for HIV-Infected Adults in the United States: 1999 to 2013. Am J Cardiol. 2016 Jan 15;117(2):214–220. PubMed PMID: 26639041; PubMed Central PMCID: PMCPMC5308060.
   PubMed Web of Science ®Google Scholar
• Palella FJ Jr., Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 2006 Sep;43(1):27–34. PubMed PMID: 16878047.
   PubMed Web of Science ®Google Scholar
• Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003 Nov 20;349(21):1993–2003. PubMed PMID: 14627784.
   PubMed Web of Science ®Google Scholar
• Brown TT, Cole SR, Li X, et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med. 2005 May 23;165(10):1179–1184. PubMed PMID: 15911733.
   PubMedGoogle Scholar
• van Welzen BJ, Mudrikova T, El Idrissi A, et al. A review of Non-Alcoholic fatty liver disease in HIV-infected patients: the next big thing? Infect Dis Ther. 2019 Mar;8(1):33–50. 10.1007/s40121-018-0229-7. PubMed PMID: 30607807; PubMed Central PMCID: PMCPMC6374241
   PubMed Web of Science ®Google Scholar
• Joy T, Keogh HM, Hadigan C, et al. Relation of body composition to body mass index in HIV-infected patients with metabolic abnormalities. J Acquir Immune Defic Syndr. 2008 Feb 1;47(2):174–184. PubMed PMID: 17971710; PubMed Central PMCID: PMCPMC4393650.
   PubMed Web of Science ®Google Scholar
• Murata H, Hruz PW, Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem. 2000 Jul 7;275(27):20251–20254. PubMed PMID: 10806189.
   PubMed Web of Science ®Google Scholar
• McLaughlin M, Walsh S, Galvin S. Dolutegravir-induced hyperglycaemia in a patient living with HIV. J Antimicrob Chemother. 2018 Jan 1;73(1):258–260. PubMed PMID: 29077869.
   PubMed Web of Science ®Google Scholar
• Fong PS, Flynn DM, Evans CD, et al. Integrase strand transfer inhibitor-associated diabetes mellitus: A case report. Int J STD AIDS. 2017 May;28(6):626–628. PubMed PMID: 27733708.
   PubMed Web of Science ®Google Scholar
• Feeney ER, Mallon PW. Insulin resistance in treated HIV infection. Best Pract Res Clin Endocrinol Metab. 2011 Jun;25(3):443–458. PubMed PMID: 21663838.
   PubMed Web of Science ®Google Scholar
• Sax PE, Erlandson KM, Lake JE, et al. Weight Gain Following Initiation of Antiretroviral Therapy: risk Factors in Randomized Comparative Clinical Trials. Clin Infect Dis. 2019 Oct 14. DOI:10.1093/cid/ciz999. PubMed PMID: 31606734.
   Web of Science ®Google Scholar
• Bourgi K, Rebeiro PF, Turner M, et al. Greater Weight Gain in Treatment Naive Persons Starting Dolutegravir-Based Antiretroviral Therapy. Clin Infect Dis. 2019 May 17. DOI:10.1093/cid/ciz407. PubMed PMID: 31100116.
   PubMedGoogle Scholar
• Kerchberger AM, Sheth AN, Angert CD, et al. Weight Gain Associated with Integrase Stand Transfer Inhibitor Use in Women. Clin Infect Dis. 2019 Aug 28. DOI:10.1093/cid/ciz853. PubMed PMID: 31504324.
   PubMed Web of Science ®Google Scholar
• Norwood J, Turner M, Bofill C, et al. Brief Report: weight Gain in Persons With HIV Switched From Efavirenz-Based to Integrase Strand Transfer Inhibitor-Based Regimens. J Acquir Immune Defic Syndr. 2017 Dec 15;76(5):527–531. PubMed PMID: 28825943; PubMed Central PMCID: PMCPMC5680113.
   PubMed Web of Science ®Google Scholar
• Strategies for Management of Anti-Retroviral Therapy I, Groups DADS. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS. 2008 Sep 12;22(14):F17–24. PubMed PMID: 18753925; PubMed Central PMCID: PMCPMC2644883.
   PubMed Web of Science ®Google Scholar
• Elion RA, Althoff KN, Zhang J, et al. Recent Abacavir Use Increases Risk of Type 1 and Type 2 Myocardial Infarctions Among Adults With HIV. J Acquir Immune Defic Syndr. 2018 May 1;78(1):62–72. PubMed PMID: 29419568; PubMed Central PMCID: PMCPMC5889316.
   PubMed Web of Science ®Google Scholar
• Feinstein MJ. Cardiovascular disease risk assessment in HIV: navigating data-sparse zones. Heart. 2016 Aug 1;102(15):1157–1158. PubMed PMID: 27406719.
   PubMed Web of Science ®Google Scholar
• Feinstein MJ, Nance RM, Drozd DR, et al. Assessing and refining Myocardial infarction risk estimation among patients with human immunodeficiency virus: a study by the centers for AIDS research network of integrated clinical systems. JAMA Cardiol. 2017 Feb 1;2(2):155–162. PubMed PMID: 28002550; PubMed Central PMCID: PMCPMC5310962.
   PubMed Web of Science ®Google Scholar
• Thompson-Paul AM, Lichtenstein KA, Armon C, et al. Cardiovascular Disease Risk Prediction in the HIV Outpatient Study. Clin Infect Dis. 2016 Dec 1;63(11):1508–1516. PubMed PMID: 27613562; PubMed Central PMCID: PMCPMC5624518.
   PubMed Web of Science ®Google Scholar
• Triant VA, Perez J, Regan S, et al. Cardiovascular Risk Prediction Functions Underestimate Risk in HIV Infection. Circulation. 2018 May 22;137(21):2203–2214. PubMed PMID: 29444987; PubMed Central PMCID: PMCPMC6157923.
   PubMed Web of Science ®Google Scholar
• Wiggins BS, Lamprecht DG Jr., Page RL 2nd, et al. Recommendations for Managing Drug-Drug Interactions with Statins and HIV Medications. Am J Cardiovasc Drugs. 2017 Oct;17(5):375–389. 10.1007/s40256-017-0222-7. PubMed PMID: 28364370
   PubMed Web of Science ®Google Scholar
• Brocklehurst P, French R. The association between maternal HIV infection and perinatal outcome: a systematic review of the literature and meta-analysis. Br J Obstet Gynaecol. 1998 Aug;105(8):836–848. PubMed PMID: 9746375.
   PubMedGoogle Scholar
• Jeong H. Altered drug metabolism during pregnancy: hormonal regulation of drug-metabolizing enzymes. Expert Opin Drug Metab Toxicol. 2010 Jun;6(6):689–699. PubMed PMID: 20367533; PubMed Central PMCID: PMCPMC3686288.
   PubMed Web of Science ®Google Scholar
• Notarianni LJ. Plasma protein binding of drugs in pregnancy and in neonates. Clin Pharmacokinet. 1990 Jan;18(1):20–36. PubMed PMID: 2178848.
   PubMed Web of Science ®Google Scholar
• Hodge LS, Tracy TS. Alterations in drug disposition during pregnancy: implications for drug therapy. Expert Opin Drug Metab Toxicol. 2007 Aug;3(4):557–571. PubMed PMID: 17696806.
   PubMed Web of Science ®Google Scholar
• Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States. [updated 2019 Jan 7]. Available from: https://aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdf.
   Google Scholar
• Zash R, Makhema J, Shapiro RL. Neural-Tube Defects with Dolutegravir Treatment from the Time of Conception. N Engl J Med. 2018 Sep 6;379(10):979–981. PubMed PMID: 30037297; PubMed Central PMCID: PMCPMC6550482.
   PubMed Web of Science ®Google Scholar
• Zash R, Holmes L, Diseko M, et al. Neural-Tube Defects and Antiretroviral Treatment Regimens in Botswana. N Engl J Med. 2019 Jul 22;381:827–840. PubMed PMID: 31329379.
   PubMed Web of Science ®Google Scholar
• Schalkwijk S, Colbers A, Konopnicki D, et al. First reported use of elvitegravir and cobicistat during pregnancy. AIDS. 2016 Mar 13;30(5):807–808. PubMed PMID: 26913711.
   PubMed Web of Science ®Google Scholar
• Momper JD, Best BM, Wang J, et al. Elvitegravir/cobicistat pharmacokinetics in pregnant and postpartum women with HIV. AIDS. 2018 Nov 13;32(17):2507–2516. PubMed PMID: 30134297; PubMed Central PMCID: PMCPMC6209536.
   PubMed Web of Science ®Google Scholar
• Scarsi KK, Darin KM, Nakalema S, et al. Unintended Pregnancies Observed With Combined Use of the Levonorgestrel Contraceptive Implant and Efavirenz-based Antiretroviral Therapy: A Three-Arm Pharmacokinetic Evaluation Over 48 Weeks. Clin Infect Dis. 2016 Mar 15;62(6):675–682. PubMed PMID: 26646680; PubMed Central PMCID: PMCPMC4772838.
   PubMed Web of Science ®Google Scholar
• Scarsi K, Cirrincione K, Nakalema S, et al. Double-dose levonorgestrel implant does not fully overcome interaction with efavirenz. CROI 2019. Seattle. 2019 Mar 4–7. Oral abstract 51.
   Google Scholar
• Radix A, Sevelius J, Deutsch MB. Transgender women, hormonal therapy and HIV treatment: a comprehensive review of the literature and recommendations for best practices. J Int AIDS Soc. 2016;19(3 Suppl 2):20810. PubMed PMID: 27431475; PubMed Central PMCID: PMCPMC4949308.
   PubMedGoogle Scholar
• Braun HM, Candelario J, Hanlon CL, et al. Transgender Women Living with HIV Frequently Take Antiretroviral Therapy and/or Feminizing Hormone Therapy Differently Than Prescribed Due to Drug-Drug Interaction Concerns. LGBT Health. 2017 Oct;4(5):371–375. PubMed PMID: 28876170; PubMed Central PMCID: PMCPMC5661861.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control. Announcement: monitoring Selected National HIV Prevention and Care Objectives. MMWR Morb Mortal Wkly Rep. 2017 Jul 28;66(29):794. PubMed PMID: 28749920; PubMed Central PMCID: PMCPMC5657813.
   PubMedGoogle Scholar
• Risher KA, Kapoor S, Daramola AM, et al. Challenges in the Evaluation of Interventions to Improve Engagement Along the HIV Care Continuum in the United States: A Systematic Review. AIDS Behav. 2017 Jul;21(7):2101–2123. 10.1007/s10461-017-1687-8. PubMed PMID: 28120257; PubMed Central PMCID: PMCPMC5843766
   PubMed Web of Science ®Google Scholar
• Mugavero MJ, Amico KR, Horn T, et al. The state of engagement in HIV care in the United States: from cascade to continuum to control. Clin Infect Dis. 2013 Oct;57(8):1164–1171. PubMed PMID: 23797289.
   PubMed Web of Science ®Google Scholar
• Rao D, Feldman BJ, Fredericksen RJ, et al. A structural equation model of HIV-related stigma, depressive symptoms, and medication adherence. AIDS Behav. 2012 Apr;16(3):711–716. PubMed PMID: 21380495; PubMed Central PMCID: PMCPMC3314086.
   PubMed Web of Science ®Google Scholar
• Golin C, Isasi F, Bontempi JB, et al. Secret pills: HIV-positive patients’ experiences taking antiretroviral therapy in North Carolina. AIDS Educ Prev. 2002 Aug;14(4):318–329. PubMed PMID: 12212718
   PubMed Web of Science ®Google Scholar
• Warren-Jeanpiere L, Dillaway H, Hamilton P, et al. Taking it one day at a time: african American women aging with HIV and co-morbidities. AIDS Patient Care STDS. 2014 Jul;28(7):372–380. PubMed PMID: 24933093; PubMed Central PMCID: PMCPMC4074760.
   PubMed Web of Science ®Google Scholar
• Turan B, Smith W, Cohen MH, et al. Mechanisms for the Negative Effects of Internalized HIV-Related Stigma on Antiretroviral Therapy Adherence in Women: the Mediating Roles of Social Isolation and Depression. J Acquir Immune Defic Syndr. 2016 Jun 1;72(2):198–205. PubMed PMID: 26885803; PubMed Central PMCID: PMCPMC4868649.
   PubMed Web of Science ®Google Scholar
• Aidala AA, Wilson MG, Shubert V, et al. Housing Status, Medical Care, and Health Outcomes Among People Living With HIV/AIDS: A Systematic Review. Am J Public Health. 2016 Jan;106(1):e1–e23. PubMed PMID: 26562123; PubMed Central PMCID: PMCPMC4695926.
   PubMedGoogle Scholar
• Sullivan TP. The intersection of intimate partner violence and HIV: detection, disclosure, discussion, and implications for treatment adherence. Top Antivir Med. 2019 May;27(2):84–87. PubMed PMID: 31136996; PubMed Central PMCID: PMCPMC6550354.
   PubMedGoogle Scholar
• Wohl AR, Garland WH, Wu J, et al. A youth-focused case management intervention to engage and retain young gay men of color in HIV care. AIDS Care. 2011 Aug;23(8):988–997. PubMed PMID: 21390879.
   PubMed Web of Science ®Google Scholar
• Terzian AS, Irvine MK, Hollod LM, et al. Effect of HIV Housing Services on Engagement in Care and Treatment, New York City, 2011. AIDS Behav. 2015 Nov;19(11):2087–2096. 10.1007/s10461-015-1003-4. PubMed PMID: 25631320; PubMed Central PMCID: PMCPMC4598342
   PubMed Web of Science ®Google Scholar
• Bradford JB, Coleman S, Cunningham W. HIV System Navigation: an emerging model to improve HIV care access. AIDS Patient Care STDS. 2007;21 Suppl 1:S49–58. PubMed PMID: 17563290.
   PubMed Web of Science ®Google Scholar
• Naar-King S, Bradford J, Coleman S, et al. Retention in care of persons newly diagnosed with HIV: outcomes of the Outreach Initiative. AIDS Patient Care STDS. 2007;21 Suppl 1:S40–8. PubMed PMID: 17563289.
   PubMed Web of Science ®Google Scholar
• Chander G, Himelhoch S, Moore RD. Substance abuse and psychiatric disorders in HIV-positive patients: epidemiology and impact on antiretroviral therapy. Drugs. 2006;66(6):769–789. PubMed PMID: 16706551.
   PubMed Web of Science ®Google Scholar
• Whetten K, Reif S, Whetten R, et al. Trauma, mental health, distrust, and stigma among HIV-positive persons: implications for effective care. Psychosom Med. 2008 Jun;70(5):531–538. PubMed PMID: 18541904.
   PubMed Web of Science ®Google Scholar
• Bengtson AM, Pence BW, Mimiaga MJ, et al. Depressive Symptoms and Engagement in Human Immunodeficiency Virus Care Following Antiretroviral Therapy Initiation. Clin Infect Dis. 2019 Jan 18;68(3):475–481. PubMed PMID: 29901695; PubMed Central PMCID: PMCPMC6336906.
   PubMed Web of Science ®Google Scholar
• Pence BW, Gaynes BN. Falling through the cracks: the gaps between depression prevalence, diagnosis, treatment, and response in HIV care. AIDS. 2012 Mar 13;26(5):656–658. PubMed PMID: 22398574; PubMed Central PMCID: PMCPMC3691843.
   PubMed Web of Science ®Google Scholar
• Altice FL, Bruce RD, Lucas GM, et al. HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study. J Acquir Immune Defic Syndr. 2011 Mar 1;56 Suppl 1:S22–32. PubMed PMID: 21317590; PubMed Central PMCID: PMCPMC3263431.
   PubMed Web of Science ®Google Scholar
• Cunningham CO, Sohler NL, Cooperman NA, et al. Strategies to improve access to and utilization of health care services and adherence to antiretroviral therapy among HIV-infected drug users. Subst Use Misuse. 2011;46(2–3):218–232. PubMed PMID: 21303242; PubMed Central PMCID: PMCPMC3150583.
   PubMed Web of Science ®Google Scholar
• Clay PG, Yuet WC, Moecklinghoff CH, et al. A meta-analysis comparing 48-week treatment outcomes of single and multi-tablet antiretroviral regimens for the treatment of people living with HIV. AIDS Res Ther. 2018 Oct 30;15(1):17. 10.1186/s12981-018-0204-0. PubMed PMID: 30373620; PubMed Central PMCID: PMCPMC6206661
   PubMed Web of Science ®Google Scholar
• Michienzi SM, Schriever CA, Badowski ME. Abacavir/lamivudine/dolutegravir single tablet regimen in patients with human immunodeficiency virus and end-stage renal disease on hemodialysis. Int J STD AIDS. 2019 Feb;30(2):181–187. PubMed PMID: 30381029.
   PubMed Web of Science ®Google Scholar
• Emu B, Fessel J, Schrader S, et al. Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1. N Engl J Med. 2018 Aug 16;379(7):645–654. PubMed PMID: 30110589.
   PubMed Web of Science ®Google Scholar
• Hazra R, Siberry GK, Mofenson LM. Growing up with HIV: children, adolescents, and young adults with perinatally acquired HIV infection. Annu Rev Med. 2010;61:169–185. PubMed PMID: 19622036.
   PubMed Web of Science ®Google Scholar
• Rudy BJ, Murphy DA, Harris DR, et al. Prevalence and interactions of patient-related risks for nonadherence to antiretroviral therapy among perinatally infected youth in the United States. AIDS Patient Care STDS. 2010 Feb;24(2):97–104. PubMed PMID: 20059354; PubMed Central PMCID: PMCPMC2859763.
   PubMed Web of Science ®Google Scholar
• MacDonell K, Naar-King S, Huszti H, et al. Barriers to medication adherence in behaviorally and perinatally infected youth living with HIV. AIDS Behav. 2013 Jan;17(1):86–93. PubMed PMID: 23142855; PubMed Central PMCID: PMCPMC3549030.
   PubMed Web of Science ®Google Scholar
• Ryscavage P, Anderson EJ, Sutton SH, et al. Clinical outcomes of adolescents and young adults in adult HIV care. J Acquir Immune Defic Syndr. 2011 Oct 1;58(2):193–197. PubMed PMID: 21826014.
   PubMed Web of Science ®Google Scholar
• Straub DM, Tanner AE. Health-care transition from adolescent to adult services for young people with HIV. Lancet Child Adolesc Health. 2018 Mar;2(3):214–222. PubMed PMID: 30169256.
   PubMedGoogle Scholar
• Naar-King S, Templin T, Wright K, et al. Psychosocial factors and medication adherence in HIV-positive youth. AIDS Patient Care STDS. 2006 Jan;20(1):44–47. PubMed PMID: 16426155.
   PubMed Web of Science ®Google Scholar
• Mellins CA, Brackis-Cott E, Leu CS, et al. Rates and types of psychiatric disorders in perinatally human immunodeficiency virus-infected youth and seroreverters. J Child Psychol Psychiatry. 2009 Sep;50(9):1131–1138. PubMed PMID: 19298479; PubMed Central PMCID: PMCPMC2775808.
   PubMed Web of Science ®Google Scholar
• Van Dyke RB, Patel K, Siberry GK, et al. Antiretroviral treatment of US children with perinatally acquired HIV infection: temporal changes in therapy between 1991 and 2009 and predictors of immunologic and virologic outcomes. J Acquir Immune Defic Syndr. 2011 Jun 1;57(2):165–173. PubMed PMID: 21407086; PubMed Central PMCID: PMCPMC3125481.
   PubMed Web of Science ®Google Scholar
• Belzer ME, Kolmodin MacDonell K, Clark LF, et al. Acceptability and Feasibility of a Cell Phone Support Intervention for Youth Living with HIV with Nonadherence to Antiretroviral Therapy. AIDS Patient Care STDS. 2015 Jun;29(6):338–345. PubMed PMID: 25928772; PubMed Central PMCID: PMCPMC4516960.
   PubMed Web of Science ®Google Scholar
• Mimiaga MJ, Kuhns LM, Biello KB, et al. Positive STEPS - a randomized controlled efficacy trial of an adaptive intervention for strengthening adherence to antiretroviral HIV treatment among youth: study protocol. BMC Public Health. 2018 Jul 13;18(1):867. 10.1186/s12889-018-5815-9. PubMed PMID: 30001703; PubMed Central PMCID: PMCPMC6043988
   PubMedGoogle Scholar
• Lodi S, Phillips A, Touloumi G, et al. Time from human immunodeficiency virus seroconversion to reaching CD4+ cell count thresholds <200, <350, and <500 Cells/mm(3): assessment of need following changes in treatment guidelines. Clin Infect Dis. 2011 Oct;53(8):817–825. PubMed PMID: 21921225.
   PubMed Web of Science ®Google Scholar
• Sabin CA, Smith CJ, d'Arminio Monforte A, et al. Response to combination antiretroviral therapy: variation by age. AIDS. 2008 Jul 31;22(12):1463–1473. PubMed PMID: 18614870.
   PubMed Web of Science ®Google Scholar
• Nogueras M, Navarro G, Anton E, et al. Epidemiological and clinical features, response to HAART, and survival in HIV-infected patients diagnosed at the age of 50 or more. BMC Infect Dis. 2006 Nov 6;6:159. PubMed PMID: 17087819; PubMed Central PMCID: PMCPMC1654166.
   PubMed Web of Science ®Google Scholar
• Grabar S, Kousignian I, Sobel A, et al. Immunologic and clinical responses to highly active antiretroviral therapy over 50 years of age. Results from the French Hospital Database on HIV. AIDS. 2004 Oct 21;18(15):2029–2038. PubMed PMID: 15577624
   PubMed Web of Science ®Google Scholar
• Viard JP, Mocroft A, Chiesi A, et al. Influence of age on CD4 cell recovery in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy: evidence from the EuroSIDA study. J Infect Dis. 2001 Apr 15;183(8):1290–1294. PubMed PMID: 11262215.
   PubMed Web of Science ®Google Scholar
• Tracy LA, Struble K, Firnhaber C, et al. Age differences by sex in antiretroviral-naive participants: pooled analysis from randomized clinical trials. J Assoc Nurses AIDS Care. 2018 May - Jun;29(3):371–382. PubMed PMID: 29475784; PubMed Central PMCID: PMCPMC5911400.
   PubMed Web of Science ®Google Scholar
• Edwards JK, Cole SR, Westreich D, et al. Age at Entry Into Care, Timing of Antiretroviral Therapy Initiation, and 10-Year Mortality Among HIV-Seropositive Adults in the United States. Clin Infect Dis. 2015 Oct 1;61(7):1189–1195. PubMed PMID: 26082505; PubMed Central PMCID: PMCPMC4560906.
   PubMed Web of Science ®Google Scholar
• Horberg MA, Hurley LB, Klein DB, et al. The HIV care cascade measured over time and by age, sex, and race in a large national integrated care system. AIDS Patient Care STDS. 2015 Nov;29(11):582–590. PubMed PMID: 26505968.
   PubMed Web of Science ®Google Scholar
• Deeks SG. HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med. 2011;62:141–155. PubMed PMID: 21090961; PubMed Central PMCID: PMCPMC3759035.
   PubMed Web of Science ®Google Scholar
• Hasse B, Ledergerber B, Furrer H, et al. Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. Clin Infect Dis. 2011 Dec;53(11):1130–1139. PubMed PMID: 21998280.
   PubMed Web of Science ®Google Scholar
• Smit M, Brinkman K, Geerlings S, et al. Future challenges for clinical care of an ageing population infected with HIV: a modelling study. Lancet Infect Dis. 2015 Jul;15(7):810–818. PubMed PMID: 26070969; PubMed Central PMCID: PMCPMC4528076.
   PubMed Web of Science ®Google Scholar
• Ware D, Palella FJ Jr., Chew KW, et al. Prevalence and trends of polypharmacy among HIV-positive and -negative men in the Multicenter AIDS Cohort Study from 2004 to 2016. PLoS One. 2018;13(9):e0203890. PubMed PMID: 30204807; PubMed Central PMCID: PMCPMC6133387.
   PubMed Web of Science ®Google Scholar
• Schouten J, Wit FW, Stolte IG, et al. Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study. Clin Infect Dis. 2014 Dec 15;59(12):1787–1797. PubMed PMID: 25182245.
   PubMed Web of Science ®Google Scholar
• Desquilbet L, Jacobson LP, Fried LP, et al. HIV-1 infection is associated with an earlier occurrence of a phenotype related to frailty. J Gerontol A Biol Sci Med Sci. 2007 Nov;62(11):1279–1286. PubMed PMID: 18000149
   PubMed Web of Science ®Google Scholar
• Schrack JA, Althoff KN, Jacobson LP, et al. Accelerated longitudinal gait speed decline in HIV-Infected older men. J Acquir Immune Defic Syndr. 2015 Dec 1;70(4):370–376. PubMed PMID: 26102450; PubMed Central PMCID: PMCPMC4624470.
   PubMed Web of Science ®Google Scholar
• Schrack JA, Jacobson LP, Althoff KN, et al. Effect of HIV-infection and cumulative viral load on age-related decline in grip strength. AIDS. 2016 Nov 13;30(17):2645–2652. PubMed PMID: 27603294; PubMed Central PMCID: PMCPMC5083134.
   PubMed Web of Science ®Google Scholar
• Johs NA, Wu K, Tassiopoulos K, et al. Disability Among Middle-Aged and Older Persons With Human Immunodeficiency Virus Infection. Clin Infect Dis. 2017 Jul 1;65(1):83–91. PubMed PMID: 28369402; PubMed Central PMCID: PMCPMC5815567.
   PubMed Web of Science ®Google Scholar
• Sharma A, Hoover DR, Shi Q, et al. Longitudinal study of falls among HIV-infected and uninfected women: the role of cognition. Antivir Ther. 2018;23(2):179–190. PubMed PMID: 28933703; PubMed Central PMCID: PMCPMC5862760.
   PubMed Web of Science ®Google Scholar
• Tassiopoulos K, Abdo M, Wu K, et al. Frailty is strongly associated with increased risk of recurrent falls among older HIV-infected adults. AIDS. 2017 Oct 23;31(16):2287–2294. PubMed PMID: 28991026; PubMed Central PMCID: PMCPMC5654616.
   PubMed Web of Science ®Google Scholar
• Erlandson KM, Allshouse AA, Jankowski CM, et al. Relationship of physical function and quality of life among persons aging with HIV infection. AIDS. 2014 Aug 24;28(13):1939–1943. PubMed PMID: 24992000; PubMed Central PMCID: PMCPMC4380343.
   PubMed Web of Science ®Google Scholar
• Jacks A, Wainwright DA, Salazar L, et al. Neurocognitive deficits increase risk of poor retention in care among older adults with newly diagnosed HIV infection. AIDS. 2015 Aug 24;29(13):1711–1714. PubMed PMID: 26372282.
   PubMed Web of Science ®Google Scholar
• Grov C, Golub SA, Parsons JT, et al. Loneliness and HIV-related stigma explain depression among older HIV-positive adults. AIDS Care. 2010 May;22(5):630–639. PubMed PMID: 20401765; PubMed Central PMCID: PMCPMC2936670.
   PubMed Web of Science ®Google Scholar
• Llibre JM, Hung CC, Brinson C, et al. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies. Lancet. 2018 Mar 3;391(10123):839–849. PubMed PMID: 29310899.
   PubMed Web of Science ®Google Scholar
• Perez-Molina JA, Rubio R, Rivero A, et al. Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial. Lancet Infect Dis. 2015 Jul;15(7):775–784. PubMed PMID: 26062881.
   PubMed Web of Science ®Google Scholar
• Fabbiani M, Gagliardini R, Ciccarelli N, et al. Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial. J Antimicrob Chemother. 2018 Jul 1;73(7):1955–1964. PubMed PMID: 29668978.
   PubMed Web of Science ®Google Scholar
• Pulido F, Ribera E, Lagarde M, et al. Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial. Clin Infect Dis. 2017 Nov 29;65(12):2112–2118. PubMed PMID: 29020293.
   PubMed Web of Science ®Google Scholar
• Arribas JR, Girard PM, Landman R, et al. Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial. Lancet Infect Dis. 2015 Jul;15(7):785–792. PubMed PMID: 26062880.
   PubMed Web of Science ®Google Scholar
• Capetti AF, Cossu MV, Orofino G, et al. A dual regimen of ritonavir/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48 weeks’ observational data. BMC Infect Dis. 2017 Sep 30;17(1):658. 10.1186/s12879-017-2755-4. PubMed PMID: 28964268; PubMed Central PMCID: PMCPMC5622573
   PubMedGoogle Scholar
• Wheeler J, Chan S, Harrigan PR, et al. Dolutegravir with boosted darunavir treatment simplification for the transmitted HIV thymidine analog resistance in Manitoba, Canada. Int J STD AIDS. 2018 Apr;29(5):520–522. PubMed PMID: 29513131.
   PubMed Web of Science ®Google Scholar
• Taiwo BO, Marconi VC, Berzins B, et al. Dolutegravir Plus Lamivudine Maintains Human Immunodeficiency Virus-1 Suppression Through Week 48 in a Pilot Randomized Trial. Clin Infect Dis. 2018 May 17;66(11):1794–1797. PubMed PMID: 29293895; PubMed Central PMCID: PMCPMC5961309.
   PubMed Web of Science ®Google Scholar
• Cahn P, Madero JS, Arribas JR, et al. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. Lancet. 2019 Jan 12;393(10167):143–155. PubMed PMID: 30420123.
   PubMed Web of Science ®Google Scholar
• Margolis DA, Gonzalez-Garcia J, Stellbrink HJ, et al. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. Lancet. 2017 Sep 23;390(10101):1499–1510. PubMed PMID: 28750935.
   PubMed Web of Science ®Google Scholar
• Bichko V, Rogovoy B, Koryakova A, et al. Pre-clinical pharmacokinetics of elsufavirine/VM1500A long-acting injectable formulations. International Antiviral Society-USA. 2017. Poster WEPEA0190.
   Google Scholar
• Gulick RM, Flexner C. Long-Acting HIV Drugs for Treatment and Prevention. Annu Rev Med. 2019 Jan 27;70:137–150. PubMed PMID: 30355266.
   PubMed Web of Science ®Google Scholar
• Cohen YZ, Caskey M. Broadly neutralizing antibodies for treatment and prevention of HIV-1 infection. Curr Opin HIV AIDS. 2018 Jul;13(4):366–373. PubMed PMID: 29697469.
   PubMed Web of Science ®Google Scholar
• Kumar R, Qureshi H, Deshpande S, et al. Broadly neutralizing antibodies in HIV-1 treatment and prevention. Ther Adv Vaccines Immunother. 2018 Aug;6(4):61–68. PubMed PMID: 30345419; PubMed Central PMCID: PMCPMC6187420.
   PubMedGoogle Scholar
• Mendoza P, Gruell H, Nogueira L, et al. Combination therapy with anti-HIV-1 antibodies maintains viral suppression. Nature. 2018 Sep;561(7724):479–484. PubMed PMID: 30258136; PubMed Central PMCID: PMCPMC6166473.
   PubMed Web of Science ®Google Scholar
• Gautam R, Nishimura Y, Gaughan N, et al. A single injection of crystallizable fragment domain-modified antibodies elicits durable protection from SHIV infection. Nat Med. 2018 May;24(5):610–616. PubMed PMID: 29662199; PubMed Central PMCID: PMCPMC5989326.
   PubMed Web of Science ®Google Scholar
• Nakata H, Amano M, Koh Y, et al. Activity against human immunodeficiency virus type 1, intracellular metabolism, and effects on human DNA polymerases of 4ʹ-ethynyl-2-fluoro-2ʹ-deoxyadenosine. Antimicrob Agents Chemother. 2007 Aug;51(8):2701–2708. PubMed PMID: 17548498; PubMed Central PMCID: PMCPMC1932487.
   PubMed Web of Science ®Google Scholar
• Barrett SE, Teller RS, Forster SP, et al. Extended-Duration MK-8591-Eluting Implant as a Candidate for HIV Treatment and Prevention. Antimicrob Agents Chemother. 2018 Oct;62(10). DOI:10.1128/AAC.01058-18. PubMed PMID: 30012772; PubMed Central PMCID: PMCPMC6153840.
   Web of Science ®Google Scholar
• Moffatt K, Wang Y, Raj Singh TR, et al. Microneedles for enhanced transdermal and intraocular drug delivery. Curr Opin Pharmacol. 2017 Oct;36:14–21. PubMed PMID: 28780407.
   PubMed Web of Science ®Google Scholar
• Stewart SA, Dominguez-Robles J, Donnelly RF, et al. Implantable Polymeric Drug Delivery Devices: classification, Manufacture, Materials, and Clinical Applications. Polymers (Basel). 2018 Dec 12;10(12):1379. PubMed PMID: 30961303; PubMed Central PMCID: PMCPMC6401754.
   PubMed Web of Science ®Google Scholar
• Novikova M, Zhang Y, Freed EO, et al. Multiple Roles of HIV-1 Capsid during the Virus Replication Cycle. Virol Sin. 2019 Apr;34(2):119–134. PubMed PMID: 31028522; PubMed Central PMCID: PMCPMC6513821.
   PubMed Web of Science ®Google Scholar
• Rutsaert S, Steens JM, Gineste P, et al. Safety, tolerability and impact on viral reservoirs of the addition to antiretroviral therapy of ABX464, an investigational antiviral drug, in individuals living with HIV-1: a Phase IIa randomised controlled study. J Virus Erad. 2019 Jan 1;5(1):10–22. PubMed PMID: 30800421; PubMed Central PMCID: PMCPMC6362909
   PubMed Web of Science ®Google Scholar
• Cohen MS, Chen YQ, McCauley M, et al. Antiretroviral Therapy for the Prevention of HIV-1 Transmission. N Engl J Med. 2016 Sep 1;375(9):830–839. PubMed PMID: 27424812; PubMed Central PMCID: PMCPMC5049503.
   PubMed Web of Science ®Google Scholar
• Cohn SE, Haddad LB, Sheth AN, et al. Parenting Desires Among Individuals Living With Human Immunodeficiency Virus in the United States. Open Forum Infect Dis. 2018 Oct;5(10):ofy232. PubMed PMID: 30302356; PubMed Central PMCID: PMCPMC6171566.
   PubMed Web of Science ®Google Scholar